Antiangiogenic agents, generally antibodies or tyrosine-kinase inhibitors that target the
VEGF–VEGFR pathway, are currently among the few combination partners clinically proven …

The field of oncology has witnessed an extraordinary surge in the application of big data and
artificial intelligence (AI). AI development has made multiscale and multimodal data fusion …

Fluorescence imaging in the second near‐infrared window (NIR‐II) is burgeoning because
of its higher imaging fidelity in monitoring physiological and pathological processes than …

Since human skin is an immune organ, a large number of immune cells are distributed in the
epidermis and the dermis of the skin. Transdermal immunotherapy shows great therapeutic …

Hepatocellular carcinoma (HCC) is a major global healthcare challenge, with> 1 million
patients predicted to be affected annually by 2025 1. In contrast to other cancers, both …

Due to the lack of treatment options, there remains a need to advance new therapeutics in
hepatocellular carcinoma (HCC). The traditional approach moves from initial molecular …

The gut microbiome can play a crucial role in hepatocellular carcinoma (HCC) progression
through the enterohepatic circulation, primarily acting via metabolic reprogramming and …

Lysosome targeting chimeras (LYTACs) have emerged as a powerful modality that can
eliminate traditionally undruggable extracellular tumor-related pathogenic proteins, but their …

Liver cancer is a major global health concern, ranking among the top causes of cancer-
related deaths worldwide. Despite advances in medical research, the prognosis for liver …

Hepatocellular carcinoma (HCC) is a high mortality neoplasm which usually appears on a
cirrhotic liver. The therapeutic arsenal and subsequent prognostic outlook are intrinsically …